Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1
Highlights • We performed the first in man study with a live replication-deficient delNS1-trivalent vaccine. • Significant antibody titers to influenza strains contained in the vaccine were induced. • Seroconversion occurred most frequently in participants who were seronegative before vaccination. •...
Gespeichert in:
Veröffentlicht in: | Vaccine 2013-12, Vol.31 (52), p.6194-6200 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Highlights • We performed the first in man study with a live replication-deficient delNS1-trivalent vaccine. • Significant antibody titers to influenza strains contained in the vaccine were induced. • Seroconversion occurred most frequently in participants who were seronegative before vaccination. • A single intranasal dose was well tolerated and safe in healthy male and female participants. • No vaccine virus could be re-isolated in volunteers after immunization. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2013.10.061 |